<SEC-DOCUMENT>0001628280-22-000440-index.html : 20220106
<SEC-HEADER>0001628280-22-000440.hdr.sgml : 20220106
<ACCEPTANCE-DATETIME>20220106173034
ACCESSION NUMBER:		0001628280-22-000440
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220106
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220106
DATE AS OF CHANGE:		20220106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		22515711

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>asancusopressreleasex1422.htm
<DESCRIPTION>8-K
<TEXT>
Document 1 - file: asancusopressreleasex1422.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>finalforexecutionkkuscipde.htm
<DESCRIPTION>EX-2.1
<TEXT>
Document 2 - file: finalforexecutionkkuscipde.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex991sancusopressrelease-j.htm
<DESCRIPTION>EX-99.1
<TEXT>
Document 3 - file: ex991sancusopressrelease-j.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_0a.jpg
<TEXT>
Document 4 - file: image_0a.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_1a.jpg
<TEXT>
Document 5 - file: image_1a.jpg

</DOCUMENT>
</SEC-DOCUMENT>